182 related articles for article (PubMed ID: 24985058)
1. Potentially resectable metastatic colorectal cancer: an individualized approach to conversion therapy.
Marino D; Leone F; D'Avanzo F; Ribero D; Capussotti L; Aglietta M
Crit Rev Oncol Hematol; 2014 Dec; 92(3):218-26. PubMed ID: 24985058
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer.
Al-Hajeili M; Marshall JL; Smaglo BG
Oncology (Williston Park); 2016 Jan; 30(1):10-6. PubMed ID: 26791840
[TBL] [Abstract][Full Text] [Related]
3. [Specific treatment situations in metastatic colorectal cancer].
Arnold D; Schmoll HJ; Lang H; Knoefel WT; Ridwelski K; Trarbach T; Staib L; Kirchner T; Geissler M; Seufferlein T; Amthauer H; Riess H; Schlitt HJ; Piso P
Onkologie; 2010; 33 Suppl 4():8-18. PubMed ID: 20431307
[TBL] [Abstract][Full Text] [Related]
4. [Targeted biotherapy: a revolution in the management of patients with colorectal cancer?].
Rougier P; Mitry E
Gastroenterol Clin Biol; 2009; 33(8-9):672-80. PubMed ID: 19717258
[TBL] [Abstract][Full Text] [Related]
5. The role of biological agents in the resection of colorectal liver metastases.
Nordlinger B; Adam R; Arnold D; Zalcberg JR; Gruenberger T
Clin Oncol (R Coll Radiol); 2012 Aug; 24(6):432-42. PubMed ID: 22794325
[TBL] [Abstract][Full Text] [Related]
6. [Colorectal cancer].
Oya M; Sameshima S; Tagaya N; Takeshita E; Koketsu S; Sugamata Y; Yoshiba H; Ueno M; Fujimoto Y; Suenaga M
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1252-5. PubMed ID: 21829061
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
8. Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancer-Predictive Factors and Prognosis.
Nozawa H; Ishihara S; Kawai K; Hata K; Kiyomatsu T; Tanaka T; Nishikawa T; Otani K; Yasuda K; Sasaki K; Kaneko M; Murono K
Clin Colorectal Cancer; 2018 Mar; 17(1):e91-e97. PubMed ID: 29113730
[TBL] [Abstract][Full Text] [Related]
9. Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases.
Galizia G; De Vita F; Lieto E; Zamboli A; Morgillo F; Castellano P; Mabilia A; Auricchio A; Renda A; Ciardiello F; Orditura M
Oncol Rep; 2013 Dec; 30(6):2992-8. PubMed ID: 24126855
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
11. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study.
Taïeb J; Artru P; Paye F; Louvet C; Perez N; André T; Gayet B; Hebbar M; Goebel FM; Tournigand C; Parc R; de Gramont A
J Clin Oncol; 2005 Jan; 23(3):502-9. PubMed ID: 15659495
[TBL] [Abstract][Full Text] [Related]
12. An update on treatment advances for the first-line therapy of metastatic colorectal cancer.
Lee JJ; Chu E
Cancer J; 2007; 13(5):276-81. PubMed ID: 17921724
[TBL] [Abstract][Full Text] [Related]
13. Updated options for liver-limited metastatic colorectal cancer.
Alberts SR
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S58-62. PubMed ID: 19064408
[TBL] [Abstract][Full Text] [Related]
14. Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.
Yoshida M; Goto M; Kii T; Nishitani H; Kawabe S; Kuwakado S; Asaishi K; Miyamoto T; Higuchi K
Digestion; 2013; 87(1):59-64. PubMed ID: 23343971
[TBL] [Abstract][Full Text] [Related]
15. Prolonged survival of patients with metastatic colorectal cancer following first-line oxaliplatin-based chemotherapy with molecular targeting agents and curative surgery.
Shitara K; Matsuo K; Kondo C; Takahari D; Ura T; Inaba Y; Yamaura H; Sato Y; Kato M; Kanemitsu Y; Komori K; Ishiguro S; Sano T; Shimizu Y; Muro K
Oncology; 2011; 81(3-4):167-74. PubMed ID: 22057124
[TBL] [Abstract][Full Text] [Related]
16. Metastatic colorectal cancer: recent advances in its clinical management.
Barugel ME; Vargas C; Krygier Waltier G
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1829-47. PubMed ID: 19954294
[TBL] [Abstract][Full Text] [Related]
17. Current opinion on optimal treatment for colorectal cancer.
Price TJ; Segelov E; Burge M; Haller DG; Ackland SP; Tebbutt NC; Karapetis CS; Pavlakis N; Sobrero AF; Cunningham D; Shapiro JD
Expert Rev Anticancer Ther; 2013 May; 13(5):597-611. PubMed ID: 23617351
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
[TBL] [Abstract][Full Text] [Related]
19. Integrating targeted agents into therapeutic regimens for patients with resectable colorectal cancer.
Marshall JL
Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S63-6. PubMed ID: 19064409
[TBL] [Abstract][Full Text] [Related]
20. [Conversion therapy for synchronous colorectal liver metastases].
Morohashi H; Yokoyama H; Akasaka H; Sakamoto Y; Koyama M; Murata A; Hakamada K
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1665-7. PubMed ID: 24393882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
